Reality Check

MMIT Reality Check on Cystic Fibrosis (Dec 2018)

December 7, 2018

According to our recent payer coverage analysis for cystic fibrosis (CF) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for cystic fibrosis (CF) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CF treatments shows that more than half of the covered lives under the pharmacy benefit in health exchange programs and Medicare formularies have some type of utilization management restriction.

Trends: Even with a host of medications to treat the condition, challenges to managing CF exist, including the high cost of care, drug burden and having to get multiple medicines from more than one pharmacy. Via AIS Health.

MMIT Reality Check on Growth Hormones (Nov 2018)

November 30, 2018

According to our recent payer coverage analysis for growth hormone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for growth hormone treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for growth hormone treatments shows that more than 60% of covered lives under the pharmacy benefit in commercial formularies and health exchange programs have some type of utilization management restriction.

Trends: The market is trending toward the development of long-acting growth hormone drugs that can be administered weekly or biweekly instead of currently marketed daily growth hormones. Via AIS Health.

MMIT Reality Check on Ovarian Cancer (Nov 2018)

November 23, 2018

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for ovarian cancer treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for ovarian cancer treatments shows that across all drugs in the class, only an average of 17% of Medicare lives are not covered for at least one of the drugs.

Trends: The FDA in June expanded the label of Avastin (bevacizumab) to include its use in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for the treatment of stage III or stage IV epithelial ovarian, fallopian tube or primary peritoneal cancer following initial surgery resection. Via AIS Health.

MMIT Reality Check on Migraine (Nov 2018)

November 16, 2018

According to our recent payer coverage analysis for migraine treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for migraine treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for migraine treatments shows that about 42% of the covered lives under commercial formularies are restricted.

Trends: The launch of the CGRP inhibitors disrupts the current market dynamics, and it’s currently unclear if they will create a treatment step after generic products but before botulinum toxins or be treated roughly equal to botulinum toxins. Via AIS Health.

MMIT Reality Check on Multiple Myeloma (Nov 2018)

November 9, 2018

According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

According to our recent payer coverage analysis for multiple myeloma treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for multiple myeloma treatments shows that more than 76% of the covered lives under Medicare formularies are restricted.

Trends: In May, 2018, the FDA granted an additional indication to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone for people with newly diagnosed multiple myeloma who are not eligible for an autologous stem cell transport. Via AIS Health.

MMIT Reality Check on CLL (Nov 2018)

November 2, 2018

According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

According to our recent payer coverage analysis for chronic lymphocyctic leukemia (CLL) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for CLL treatments shows that more than half of the covered lives under Medicare formularies are restricted.

Trends: The FDA approved Verastem, Inc.’s Copiktra (duvelisib) for the treatment of adults with relapsed or refractory CLL after at least two treatments.